Market Place
Sourcing Support
Neurocrine Bio Announces Crenessity Availability for CAH Patients
20 Dec 2024 //
PR NEWSWIRE
US FDA approves Neurocrine Biosciences` genetic disorder drug
14 Dec 2024 //
REUTERS
Neurocrine Presents New KINECT®-HD Data on INGREZZA®
07 Nov 2024 //
PR NEWSWIRE
Neurocrine Biosciences to Participate in November Investor Conf
05 Nov 2024 //
PR NEWSWIRE
Neurocrine Presents INGREZZA® Data at Psych Congress 2024
04 Nov 2024 //
PR NEWSWIRE
Neurocrine Presents Data on INGREZZA® for Tardive Dyskinesia
04 Nov 2024 //
PR NEWSWIRE
Neurocrine Reports Q3 2024 Results, Raises INGREZZA Sales Guidance
30 Oct 2024 //
PR NEWSWIRE
Neurocrine Biosciences Announces Q3 2024 Financial Results Call
09 Oct 2024 //
PR NEWSWIRE
Neurocrine Presents Data On Chorea Improvements In Huntington`s
30 Sep 2024 //
PR NEWSWIRE
Neurocrine`s Crinecerfont Set To Transform CAH Market
30 Sep 2024 //
PR NEWSWIRE
Neurocrine Biosciences at TD Cowen Neuropsychiatry Summit
19 Sep 2024 //
PRESS RELEASE
Neurocrine Biosciences Updates On Luvadaxistat Phase 2 Data
12 Sep 2024 //
PR NEWSWIRE
Neurocrine halts development of schizophrenia drug as trial fails
12 Sep 2024 //
REUTERS
Nxera To Receive $35M From Neurocrine Upon Positive Phase 2 Schizophrenia Data
01 Sep 2024 //
GLOBENEWSWIRE
Neurocrine`s drug cuts schizophrenia symptoms in mid-stage study
29 Aug 2024 //
REUTERS
Neurocrine Biosciences to Participate at Investor Conferences in September
28 Aug 2024 //
PR NEWSWIRE
Nxera Pharma Reports Q2 And H1 2024 Results And Highlights
09 Aug 2024 //
GLOBENEWSWIRE
Neurocrine Biosciences To Present At Canaccord Genuity Conference
07 Aug 2024 //
PR NEWSWIRE
Neurocrine Launches INGREZZA® SPRINKLE For Easier Administration
18 Jul 2024 //
PR NEWSWIRE
Neurocrine Biosciences To Report Q2 2024 Results Via Conference Call
11 Jul 2024 //
PR NEWSWIRE
FDA Grants Priority Review For Neurocrine`s Crinecerfont In CAH
01 Jul 2024 //
PR NEWSWIRE
Neurocrine`s CAH Pediatric, Adult, Registry, Comorbidity Data At ENDO
03 Jun 2024 //
PR NEWSWIRE
Neurocrine CEO Retires, Bluebird Appoints 5th CFO In 3 Years
31 May 2024 //
ENDPTS
Neurocrine Biosciences to Participate at Investor Conferences in June
29 May 2024 //
PR NEWSWIRE
Neurocrine elevates BD chief to succeed founder and CEO
29 May 2024 //
FIERCE PHARMA
Neurocrine founder-CEO Gorman to retire in October
28 May 2024 //
REUTERS
Neurocrine To Present Phase 3 Data On CAH, Primary Adrenal Insufficiency
28 May 2024 //
PR NEWSWIRE
Neurocrine Biosciences Announces CEO Succession Plan
28 May 2024 //
PR NEWSWIRE
Neurocrine Publishes INGREZZA Phase 3 Tardive Dyskinesia Long-Term Analysis
21 May 2024 //
PR NEWSWIRE
Neurocrine Presents CAHtalyst, Hydrocortisone Data At ECE 2024
14 May 2024 //
PR NEWSWIRE
Neurocrine NBI-1076986 Phase 1 Initiation In Healthy Adults
09 May 2024 //
PR NEWSWIRE
Neurocrine CAHtalyst, Glucocorticoid Impact Data At AACE 2024
09 May 2024 //
PR NEWSWIRE
Nxera Partner Neurocrine Initiates NBI-1117567 Phase 1 Study
09 May 2024 //
GLOBENEWSWIRE
Neurocrine Initiates Phase 1 Study Of NBI-1117567 In Healthy Adults
08 May 2024 //
PR NEWSWIRE
Neurocrine CAHtalyst, Hydrocortisone Data At ECE 2024
07 May 2024 //
PR NEWSWIRE
Neurocrine At BofA Securities Healthcare Conference 2024
07 May 2024 //
PR NEWSWIRE
Neurocrine joins in on Tardive Dyskinesia Awareness Week
06 May 2024 //
FIERCE PHARMA
Neurocrine Presents Pediatric CAHtalyst™, CAHtalog™ Data At PES
03 May 2024 //
PR NEWSWIRE
Neurocrine Biosciences` Huntington`s disease drug gets FDA approval
01 May 2024 //
PRESS RELEASE
Neurocrine`s INGREZZA® SPRINKLE Capsules Approved By US FDA
30 Apr 2024 //
PR NEWSWIRE
Neurocrine launches CAH rare disease education campaign ahead of FDA submission
24 Apr 2024 //
ENDPTS
Neurocrine scores surprise win with depression drug
24 Apr 2024 //
BIOPHARAMDIVE
Neurocrine Reports Positive Phase 2 Data for NBI-1065845 in Depression
23 Apr 2024 //
PR NEWSWIRE
Voyager Selects GBA1 Program Candidate, Triggers Milestone with Neurocrine
16 Apr 2024 //
GLOBENEWSWIRE
Sentia and Neurocrine Extend Collaboration to Discover Novel CRF Peptides
16 Apr 2024 //
GLOBENEWSWIRE
Nxera Pharma Notes Successful Progress of Schizophrenia Candidate NBI-1117568
16 Apr 2024 //
GLOBENEWSWIRE
Neurocrine Biosciences Schedules Q1 2024 Financial Results Call
10 Apr 2024 //
PR NEWSWIRE
Neurocrine Announces First Dosed in Ph 2 Study Evaluating NBI-1070770
03 Apr 2024 //
PR NEWSWIRE
Endometriosis Global Clinical Trials Review 2024
02 Apr 2024 //
BUSINESSWIRE
Neurocrine Announces Initiation of Ph1 Study Evaluating NBI-1065890
28 Mar 2024 //
PR NEWSWIRE
Director Richard Pops Sells Shares of Neurocrine Biosciences Inc (NBIX)
13 Mar 2024 //
YAHOO FINANCE
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
11 Mar 2024 //
PR NEWSWIRE
Neurocrine Biosciences to Participate at Investor Conferences in March
27 Feb 2024 //
PR NEWSWIRE
Voyager Announces Selection of Development Candidate for Friedreich™s Ataxia
26 Feb 2024 //
GLOBENEWSWIRE
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results
07 Feb 2024 //
PR NEWSWIRE
Neurocrine Announces Webcast of Q4 and Year-End 2023 Financial Results
17 Jan 2024 //
PRESS RELEASE
Neurocrine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
PR NEWSWIRE
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Bio
19 Dec 2023 //
BUSINESSWIRE
Neurocrine Confirms Plans to Evaluate Muscarinic Agonist Candidates in Ph 1 Studies
06 Dec 2023 //
GLOBENEWSWIRE
Neurocrine Receives Breakthrough Therapy Designation from FDA for Crinecerfont
05 Dec 2023 //
PR NEWSWIRE
